• Publications
  • Influence
Clinical Pharmacokinetics of Mycophenolate Mofetil
SummaryThe pharmacokinetics of the immunosuppressant mycophenolate mofetil have been investigated in healthy volunteers and mainly in recipients of renal allografts. Following oral administration,Expand
The pharmacokinetic‐pharmacodynamic relationship for mycophenolate mofetil in renal transplantation
Mycophenolate mofetil, a pro‐drug for mycophenolic acid, reduces the likelihood of allograft rejection after renal transplantation. We studied the relationship between mycophenolic acidExpand
Pharmacokinetics of mycophenolate mofetil (RS61443): a short review.
Overall, the PK of MMF is reasonably straightforward and relatively unaffected by the complex pathophysiological changes involved in the management of renal transplant recipients. The ability toExpand
Pharmacokinetics and Bioavailability of Mycophenolate Mofetil in Healthy Subjects after Single‐Dose Oral and Intravenous Administration
A randomized, crossover study of 12 healthy volunteers was conducted with single, 1.5‐g doses of mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), after oral and intravenousExpand
A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney
Background. Adding a fixed dose of 1 g b.i.d. of mycophenolate mofetil (MMF) to an immunosuppressive regimen consisting of cyclosporine and prednisone results in a 50% reduction in the incidence ofExpand
Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide Gonadotropin-Releasing Hormone Antagonist Elagolix
Peptide gonadotropin-releasing hormone (GnRH) antagonists are widely used to suppress the reproductive endocrine axis in women with endometriosis, fibroids, and other nonmalignant reproductiveExpand
A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney
BACKGROUND Adding a fixed dose of 1 g b.i.d. of mycophenolate mofetil (MMF) to an immunosuppressive regimen consisting of cyclosporine and prednisone results in a 50% reduction in the incidence ofExpand
The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function
The purpose of this study was to determine the effect of renal function on the elimination and disposition of mycophenolic acid and its glucuronide metabolite (MPAG) after oral administration of theExpand
Bioavailability profile of Uceris MMX extended-release tablets compared with Entocort EC capsules in healthy volunteers
Objective To compare the pharmacokinetics of the extended-release MMX® formulation of budesonide (Uceris®) with that of Entocort® EC, an extended (controlled ileal) release formulation of budesonide.Expand
...
1
2
...